公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2006 | Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study | Chang A; Parikh P; Thongprasert S; Tan E.H; Perng R.-P; Ganzon D; CHIH-HSIN YANG ; Tsao C.-J; Watkins C; Botwood N; Thatcher N. | Journal of Thoracic Oncology | 186 | 153 | |
2016 | Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study | CHIH-HSIN YANG ; Srimuninnimit V; Ahn M.-J; CHIA-CHI LIN ; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K. | Journal of Thoracic Oncology | 22 | 20 | |
2009 | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Mok T.S; Wu Y.-L; Thongprasert S; Yang C.-H; Chu D.-T; Saijo N; Sunpaweravong P; Han B; Margono B; Ichinose Y; Nishiwaki Y; Ohe Y; CHIH-HSIN YANG ; Chewaskulyong B; Jiang H; Duffield E.L; Watkins C.L; Armour A.A; Fukuoka M. | New England Journal of Medicine | 7325 | 6479 | |
2010 | Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer. | YU-YUN SHAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Discovery medicine | 13 | 12 | |
2017 | Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival | Lee C.K.; Davies L.; Wu Y.-L.; Mitsudomi T.; Inoue A.; Rosell R.; Zhou C.; Nakagawa K.; Thongprasert S.; Fukuoka M.; Lord S.; Marschner I.; YU-KANG TU ; Gralla R.J.; Gebski V.; Mok T.; CHIH-HSIN YANG | Journal of the National Cancer Institute | 204 | 171 | |
2017 | Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): Overall survival and biomarker analyses | Mok T.S.K; Kim S.-W; Wu Y.-L; Nakagawa K; Yang J.-J; Ahn M.-J; Wang J; CHIH-HSIN YANG ; Lu Y; Atagi S; Ponce S; Shi X; Rukazenkov Y; Haddad V; Thress K.S; Soria J.-C. | Journal of Clinical Oncology | 132 | 115 | |
2015 | Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial | Soria J.-C; Wu Y.-L; Nakagawa K; Kim S.-W; CHIH-HSIN YANG ; Ahn M.-J; Wang J; Lu Y; Atagi S; Ponce S; Lee D.H; Liu Y; Yoh K; Zhou J.-Y; Shi X; Webster A; Jiang H; Mok T.S.K. | The Lancet Oncology | 353 | 315 | |
2005 | Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein | CHIH-HSIN YANG ; Huang C.-J.; Yang C.-S.; Chu Y.-C.; ANN-LII CHENG ; Whang-Peng J.; PAN-CHYR YANG | Cancer Research | 93 | 88 | |
2011 | Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations | Wu J.-Y.; JIN-YUAN SHIH ; KUAN-YU CHEN ; CHIH-HSIN YANG ; CHONG-JEN YU ; PAN-CHYR YANG | Medicine | 32 | 27 | |
2005 | Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status | Su W.-P.; CHIH-HSIN YANG ; CHONG-JEN YU ; JIN-YUAN SHIH ; CHIUN HSU ; PAN-CHYR YANG | Journal of the Formosan Medical Association | 12 | 10 | |
2002 | Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer | CHIH-HSIN YANG ; PAN-CHYR YANG ; Wang L.S.; Lee Y.C.; CHIEN-JEN CHANG ; Lui L.T.; Yen S.H.; CHIUN HSU ; ANN-LII CHENG ; Liu M.Y.; Chiang S.C.; Chen Y.M.; KWEN-TAY LUH ; Huang M.H.; Yang P.-C.; Perng R.-P. | British Journal of Cancer | 24 | 20 | |
2008 | Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial | CHIUN HSU ; SUNG-HSIN KUO ; Hu F.-C.; ANN-LII CHENG ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIA-CHI LIN ; Huang T.-C.; PAN-CHYR YANG ; CHIH-HSIN YANG | Lung Cancer | 14 | 11 | |
2001 | Gemcitabine-induced acute lipodermatosclerosis-like reaction | CHIA-YU CHU ; CHIH-HSIN YANG ; HSIEN-CHING CHIU | Acta Dermato-Venereologica | 24 | 16 | |
2017 | Genetic modifiers of progression-free survival in never-smoking lung adenocarcinoma patients treated with first-line tyrosine kinase inhibitors | Chang I.-S.; Jiang S.-S.; CHIH-HSIN YANG ; Su W.-C.; Chien L.-H.; Hsiao C.-F.; JIH-HSIANG LEE ; Chen C.-Y.; Chen C.-H.; Chang G.-C.; Wang Z.; Lo F.-Y.; KUAN-YU CHEN ; Wang W.-C.; Chen Y.-M.; Huang M.-S.; Tsai Y.-H.; Su Y.-C.; Hsieh W.-S.; Shih W.-C.; Shieh S.-H.; Yang T.-Y.; Lan Q.; Rothman N.; Chen C.-J.; Chanock S.J.; PAN-CHYR YANG ; Hsiung C.A. | American Journal of Respiratory and Critical Care Medicine | 17 | 17 | |
2012 | Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum | WEI-YU LIAO ; JIN-YUAN SHIH ; Chang G.-C.; Cheng Y.-K.; CHIH-HSIN YANG ; Chen Y.-M.; CHONG-JEN YU | Journal of Thoracic Oncology | 50 | 50 | |
2008 | Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern | SHANG-GIN WU ; YIH-LEONG CHANG ; Hsu Y.-C.; Wu J.-Y.; CHIH-HSIN YANG ; CHONG-JEN YU ; Tsai M.-F.; JIN-YUAN SHIH ; PAN-CHYR YANG | Oncologist | 72 | 67 | |
2011 | Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations | SHANG-GIN WU ; CHIH-HSIN YANG ; CHONG-JEN YU ; JIH-HSIANG LEE ; Hsu Y.-C.; YIH-LEONG CHANG ; JIN-YUAN SHIH ; PAN-CHYR YANG | Lung Cancer | 41 | 35 | |
2021 | Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey | Garrido P.; Adjei A.A.; Bajpai J.; Banerjee S.; Berghoff A.S.; Choo S.P.; Felip E.; Furness A.J.S.; Garralda E.; Haanen J.; Letsch A.; Linardou H.; Peters S.; Sessa C.; Tabernero J.; Tsang J.; CHIH-HSIN YANG ; Garassino M.C. | ESMO Open | 16 | 14 | |
2011 | Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS) | Thongprasert S; Duffield E; Saijo N; Wu Y.-L; CHIH-HSIN YANG ; Chu D.-T; Liao M; Chen Y.-M; Kuo H.-P; Negoro S; Lam K.C; Armour A; Magill P; Fukuoka M. | Journal of Thoracic Oncology | 120 | 107 | |
2023 | HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy | Yu, Helena A; Goto, Yasushi; Hayashi, Hidetoshi; Felip, Enriqueta; CHIH-HSIN YANG ; Reck, Martin; Yoh, Kiyotaka; Lee, Se-Hoon; Paz-Ares, Luis; Besse, Benjamin; Bironzo, Paolo; Kim, Dong-Wan; Johnson, Melissa L; Wu, Yi-Long; John, Thomas; Kao, Steven; Kozuki, Toshiyuki; Massarelli, Erminia; Patel, Jyoti; Smit, Egbert; Reckamp, Karen L; Dong, Qian; Shrestha, Pomy; Fan, Pang-Dian; Patel, Parul; Sporchia, Andrea; Sternberg, David W; Sellami, Dalila; Jänne, Pasi A | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 10 | 5 | |